GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Acotec Scientific Holdings 6669.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

5.37

-3.24%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥751.8m

FY2019FY2025

Net income

CN¥139.0m

FY2019FY2025

Free cash flow

CN¥169.6m

FY2019FY2025

Shareholders' equity

CN¥1.72bn

FY2019FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
RevenueCN¥751.8mCN¥534.0mCN¥473.8mCN¥395.5mCN¥354.3mCN¥226.2mCN¥145.7m
Gross profitCN¥555.5mCN¥402.7mCN¥377.4mCN¥336.4mCN¥310.1mCN¥191.0mCN¥123.5m
Research and developmentCN¥249.2mCN¥216.8mCN¥190.1mCN¥183.8mCN¥164.8mCN¥97.4mCN¥29.7m
Operating incomeCN¥155.3mCN¥64.0mCN¥25.0mCN¥72.1m−CN¥74.0m−CN¥35.0mCN¥30.3m
Net incomeCN¥139.0mCN¥52.3mCN¥14.5mCN¥70.1m−CN¥92.2m−CN¥51.1mCN¥26.9m
Diluted earnings per share0.460.170.050.23-0.33-0.250.09

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Total assetsCN¥2.18bnCN¥1.94bnCN¥1.88bnCN¥1.64bnCN¥1.52bnCN¥318.3mCN¥130.9m
Cash and short-term investmentsCN¥1.11bnCN¥944.1mCN¥1.03bnCN¥1.15bnCN¥1.33bnCN¥171.5mCN¥36.8m
Total liabilitiesCN¥457.4mCN¥364.7mCN¥366.8mCN¥156.8mCN¥116.8mCN¥646.0mCN¥87.7m
DebtCN¥285.0mCN¥202.9mCN¥234.0mCN¥47.8mCN¥24.6mCN¥175.2mCN¥19.9m
Shareholders' equityCN¥1.72bnCN¥1.57bnCN¥1.51bnCN¥1.49bnCN¥1.41bn−CN¥327.7mCN¥43.2m
Shares outstanding302m301m301m299m277m208m313m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operationsCN¥195.1mCN¥102.8m−CN¥15.0m−CN¥80.2m−CN¥12.2m−CN¥10.2mCN¥23.2m
Capital spending−CN¥25.5m−CN¥97.5m−CN¥92.9m−CN¥54.5m−CN¥24.8m−CN¥21.7m−CN¥3.1m
Free cash flowCN¥169.6mCN¥5.3m−CN¥107.9m−CN¥134.6m−CN¥37.0m−CN¥31.9mCN¥20.0m
Dividends paid————−CN¥376.8m−CN¥376.8m−CN¥376.8m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥193.3mCN¥193.3mCN¥171.1mCN¥171.1mCN¥204.8mCN¥204.8mCN¥120.8mCN¥140.9m
Gross profitCN¥136.0mCN¥136.0mCN¥125.8mCN¥125.8mCN¥151.9mCN¥151.9mCN¥92.8mCN¥108.2m
Operating income−CN¥43.9m−CN¥43.9mCN¥22.2mCN¥22.2mCN¥55.4mCN¥55.4mCN¥8.9mCN¥10.4m
Net income−CN¥47.1m−CN¥47.1mCN¥17.8mCN¥17.8mCN¥51.6mCN¥51.6mCN¥6.2mCN¥7.2m
Diluted earnings per share-0.16-0.160.060.060.170.170.020.02
Cash from operations——CN¥4.0mCN¥4.0mCN¥82.0mCN¥82.0mCN¥26.0mCN¥30.0m
Capital spending——−CN¥6.0m−CN¥6.0m−CN¥6.0m−CN¥6.0m−CN¥11.0m−CN¥13.0m
Free cash flow——−CN¥2.0m−CN¥2.0mCN¥76.0mCN¥76.0mCN¥15.0mCN¥17.0m
Total assetsCN¥2.08bnCN¥2.08bnCN¥2.18bnCN¥2.18bnCN¥2.13bnCN¥2.13bnCN¥1.66bnCN¥1.94bn
Cash and short-term investmentsCN¥940.9mCN¥940.9mCN¥1.11bnCN¥1.11bnCN¥1.16bnCN¥1.16bnCN¥809.6mCN¥944.1m
DebtCN¥66.2mCN¥66.2mCN¥285.0mCN¥108.9mCN¥275.4mCN¥90.5mCN¥202.9mCN¥39.2m
Shareholders' equityCN¥1.63bnCN¥1.63bnCN¥1.72bnCN¥1.72bnCN¥1.68bnCN¥1.68bnCN¥1.35bnCN¥1.57bn

Financial ratios

Data as of 20 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin73.9%75.4%79.6%85.0%87.5%84.4%
Operating margin16.4%11.7%5.1%18.1%-20.9%-15.5%
Net margin18.5%9.8%3.1%17.7%-26.0%-22.6%
Return on equity8.1%3.9%1.1%5.5%-6.6%15.6%
Return on assets6.4%3.1%0.9%5.0%-6.0%-16.1%
Free cash flow yield9.5%5.9%-0.7%-3.9%-0.6%-0.7%
Revenue growth20.7%12.7%19.8%30.2%56.6%55.3%
Earnings growth128.0%260.9%-79.3%-188.7%80.4%-289.8%
Current ratio5.73x8.98x10.42x12.73x14.11x0.54x
Debt to equity0.06x0.02x0.03x0.02x0.01x-0.55x
Equity ratio79.0%81.2%80.5%90.5%92.3%-103.0%
Interest coverage11.27x5.43x2.47x50.70x-16.58x-21.11x
R&D as a share of sales33.1%40.6%40.1%46.5%46.5%43.0%
Buybacks as a share of market value-0.4%0.1%-0.6%-7.9%-33.4%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue22.5%27.7%—
Operating income29.2%——
Net income25.6%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin74.5%77.6%79.4%—
Operating margin17.1%14.7%7.6%—
Net margin14.9%12.8%4.8%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings25.329.8203.263.5-30.0
Price to sales4.62.96.210.87.9

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.